Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma

Annals of Hepatology

Volumn 11, Issue 4, 2012, Pages 487-494

  Khattab, Mahmoud A ^a   Eslam, Mohammed ^a   Mousa, Yousef I ^a   Ela Adawy, Nosa ^a   Fathy, Shimaa ^a   Shatat, Mohammed ^a   Abd Aalhalim, Hesham ^a   Kamal, Amal ^a   Sharawe, Mohammed A ^a  

^a MINIA UNIVERSITY   (Egypt)

Author keywords

Adiponectin; Hepatitis C; Hepatocellular carcinoma; HOMA; Insulin resistance

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; ARTICLE; CANCER PATIENT; CANCER SIZE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HIGH RISK PATIENT; HISTOPATHOLOGY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; EGYPT; LIVER TUMOR; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; VIROLOGY;

ADULT; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; EGYPT; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84862008950     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31462-0     Document Type: Article

References (32)

1. Ferlay J, Bray F, P.P. Globocan 2002: Cancer Inci dence, Mortality and Prevalence Worldwide. IARC Press; Lyon: 2004. IARC CancerBase No. 5. version 2.0.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epide miology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
3. Bosch FX, Ribes J, Cleries R, Díaz M. Epidemiology of hepa tocellular carcinoma. Clin Liver Dis 2005; 9: 191-211.
4. Eslam M, Khattab MA, Harrison SA. Insulin resistance and hepatitis C: an evolving story. Gut 2011; 60(8): 1139-51.
5. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43(2 Suppl. 1): S99-S112.
6. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004; 27: 2444-9.
7. Wedemeyer I, Bechmann LP, Odenthal M, Jochum C, Marquitan G, Drebber U, Gerken G, et al. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: thera peutic implications for hepatitis C. J Hepatol 2009; 50: 140-9.
8. Marra F, Bertolani C. Adipokines in liver diseases. Hepato logy 2009; 50: 957-69.
9. Huang H, Park PH, McMullen MR, Nagy LE. Mechanisms for the anti-inflammatory effects of adiponectin in macropha ges. J Gastroenterol Hepatol 2008; 23(Suppl. 1): S50-S53.
10. Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activa tion of adenosine monophosphate activated protein kina se. Hepatology 2008; 47: 677-85.
11. Khattab M, Shatat MS, Eslam M, Mayada A, Hussein A, Gaber S, Harrison SA. Insulin resistance in hepatitis C geno type 4 is partially mediated by virus-Specific changes in adipocytokines. J Hepatol 2011; 54: S458A.
12. Khattab M, Shatat MS, Eslam M, Mayada A, Hussein A, Gaber S, Harrison SA. Association of Serum Adipocytokines with Liver Injury in Patients with Chronic Hepatitis C Ge notvpe 4. J Hepoatol 2011: 54: S458-S459A.
13. Bedossa P, Poynard T. An algorithm for the grading of ac tivity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
14. Bruix J, Sherman M. Management of hepatocellular carci noma. Hepatology 2005; 42: 1208 36.
15. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. Euro pean Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.
16. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a pros pectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38.
17. Wolk A, Gridley G, Svensson M, Nyrn O, McLaughlin JK, Fraumeni JF, Adam HO. Prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12: 13-21.
18. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001; 60(1): 91-106.
19. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type I IGF receptor signalling in hepatocarci nogenesis and in the resistance of hepatocarcinoma cells against drug induced apoptosis. Biochem Pharmacol 2004; 68: 1003-15.
20. Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, Handy J, et al. Adiponectin antagonizes the oncogenic ac tions of leptin in hepatocellular carcinogenesis. Hepatology 2010; 52(5): 1713-22.
21. Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, Goto E, et al. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int J Cancer 2010.
22. Liu CJ, Chen PJ, Lai MY, Liu CH, Chen CL, Kao JH, Chen DS. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infec tion. Hepatol Int 2009; 3: 364-70.
23. Chen X, Wang Y. Adiponectin and breast cancer. Med On col 2010 [Epub ahead of print].
24. Rzepka-Go'rska I, Bedner R, Cymbaluk-Ploska A, Chudecka-Głaz A. Serum adiponectin in'relation to endometrial cancer and endometrial hyperplasia with atypia in obese women. Eur J Gynaecol Oncol 2008; 29(6): 594-7.
25. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, Mantzoros CS. Serum adi ponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with pros tate cancer: a case control study. Cancer Epidemiol Bio markers Prev 2007; 16(2): 308-13.
26. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gómez-Reino JJ, Gualillo O. Changes in plasma levels of fat derived hormones adiponectin, leptin, resistin and visfatin in pa tients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1198-201.
27. Haugen F, Ranheim T, Harsem NK, Lips E, Staff AC, Drevon CA. Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expres sion. Am J Physiol Endocrinol Metab 2006; 290: E326-E333.
28. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F. Gender-specific association of adiponectin as a pre dictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 2007; 71: 1279-86.
29. Michiel DF, Oppenheim JJ. Cytokines as positive and nega tive regulators of tumor promotion and progression. Se min Cancer Biol 1992; 3(1): 3-15.
30. Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M, Telega A, et al. Serum total choleste rol and triglycerides levels in patients with lung cancer. Int J Mol Med 2000; 5(2): 201-5.
31. Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer on li pid and lipoprotein metabolism. Lipids Health Dis 2006; 5: 4.
32. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, et al. Metabolic factors and risk of hepatocellu lar carcinoma by chronic hepatitis B/C infection: a follow up study in Taiwan. Gastroenterology 2008; 135(1): 111-12.